Certolizumab pegol

biologic · immune-hematologic · Subcutaneous

Certolizumab pegol, a biologic. Humanised anti-TNFα Fab' fragment conjugated to a 40 kDa branched polyethylene glycol (PEG) moiety. Lacks… Subcutaneous half-life 14 d.

Humanised anti-TNFα Fab' fragment conjugated to a 40 kDa branched polyethylene glycol (PEG) moiety. Lacks the IgG Fc region → no complement activation, no antibody-dependent cytotoxicity, and importantly no FcRn-mediated transplacental transfer (preferred anti-TNF during pregnancy). PEGylation extends half-life and reduces immunogenicity compared to native Fab'.

Pharmacokinetics

• Subcutaneous — t½ 14.0 d · F 80% · ka 0.06633 h⁻¹ · Vd 6.3 L

Sources: PMID:25586216